Teladoc Health Inc


Want a discount? Become a member by purchasing Annual Subscription!
SKU: TDOC-1 Category:


Teladoc had another strong quarter, with solid financial results including a staggering 81% top-line growth and an organic growth of 32%. The strength in utilization has been driven by growth in visits related to non-infectious diseases and specialty care, as consumers turn to Teladoc for a broader range of conditions, as it has been all year. Non-infectious diseases have accounted for over 75% of member visits in the last quarter in the employer and health plan channels as compared to 50% in the pre-pandemic period. Additionally, the management continued to increase multi-program enrolment. Their chronic care members are now enrolled in multiple programs at a rate of 24%, up from 8% compared to the Q3 of last year. Teladoc has significantly enhanced its chronic care capabilities and these should continue to drive growth across the company’s entire portfolio of products and services. Given their long-term growth outlook, we give the company an ‘Outperform’ rating with a revised target price.

Our Report Structure:

⦁ Company Overview
⦁ Investment Thesis
⦁ Key Drivers
⦁ Historical Quarterly Statement Analysis – Income Statement & Cash Flows
⦁ Historical Quarterly Balance Sheet Analysis
⦁ Historical Annual Financial Statement Analysis
⦁ Analysis Of Key Financial Ratios
⦁ Financial Forecasts For 3 Years
⦁ Forecasting The Capital Structure & Net Debt
⦁ Discounted Cash Flow Valuation
⦁ Trading Multiples
⦁ Key Risks
⦁ Disclosures

Want unlimited access to our reports? Purchase our $99 annual subscription!